91.29
前日終値:
$91.71
開ける:
$91.92
24時間の取引高:
11.70M
Relative Volume:
1.23
時価総額:
$135.38B
収益:
$19.35B
当期純損益:
$2.78B
株価収益率:
48.83
EPS:
1.8696
ネットキャッシュフロー:
$3.82B
1週間 パフォーマンス:
+1.40%
1か月 パフォーマンス:
-5.33%
6か月 パフォーマンス:
-11.51%
1年 パフォーマンス:
-8.99%
Boston Scientific Corp Stock (BSX) Company Profile
名前
Boston Scientific Corp
セクター
電話
508-683-4000
住所
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
BSX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
BSX
Boston Scientific Corp
|
91.29 | 136.01B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
ABT
Abbott Laboratories
|
108.61 | 209.93B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
SYK
Stryker Corp
|
358.67 | 138.80B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.34 | 128.57B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.44 | 49.41B | 5.88B | 1.34B | 799.60M | 2.3489 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-03 | ダウングレード | Erste Group | Buy → Hold |
| 2025-09-08 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-06-16 | 開始されました | Leerink Partners | Outperform |
| 2025-04-16 | アップグレード | Needham | Hold → Buy |
| 2025-01-10 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-10-18 | ダウングレード | Needham | Buy → Hold |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-02-01 | アップグレード | Mizuho | Neutral → Buy |
| 2023-07-19 | 開始されました | Robert W. Baird | Outperform |
| 2023-06-30 | 開始されました | CL King | Buy |
| 2023-05-30 | 再開されました | Morgan Stanley | Overweight |
| 2023-03-29 | 開始されました | UBS | Buy |
| 2022-12-22 | 開始されました | Mizuho | Neutral |
| 2022-12-20 | 再開されました | Citigroup | Buy |
| 2022-10-18 | 開始されました | Barclays | Overweight |
| 2022-10-12 | 開始されました | Jefferies | Buy |
| 2022-07-06 | 開始されました | Wolfe Research | Outperform |
| 2022-05-27 | アップグレード | Needham | Hold → Buy |
| 2022-04-13 | 再開されました | Truist | Buy |
| 2022-03-02 | 再開されました | BofA Securities | Buy |
| 2021-12-10 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-05-26 | ダウングレード | Needham | Buy → Hold |
| 2021-05-25 | 開始されました | Barclays | Overweight |
| 2021-04-15 | 開始されました | Atlantic Equities | Overweight |
| 2020-09-17 | 開始されました | Truist | Buy |
| 2020-09-11 | 開始されました | Wolfe Research | Peer Perform |
| 2020-04-22 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | アップグレード | Goldman | Neutral → Buy |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2020-02-13 | 開始されました | Goldman | Neutral |
| 2020-02-06 | 再開されました | BTIG Research | Buy |
| 2019-12-30 | 繰り返されました | Cowen | Outperform |
| 2019-12-19 | ダウングレード | Needham | Strong Buy → Buy |
| 2019-09-05 | 再開されました | JP Morgan | Overweight |
| 2019-09-03 | 再開されました | Barclays | Overweight |
| 2019-05-13 | アップグレード | Evercore ISI | In-line → Outperform |
| 2018-11-28 | 開始されました | UBS | Buy |
| 2018-10-16 | 開始されました | Barclays | Overweight |
| 2018-10-02 | 繰り返されました | Morgan Stanley | Overweight |
| 2018-09-07 | 繰り返されました | Needham | Strong Buy |
| 2018-09-04 | アップグレード | Jefferies | Hold → Buy |
| 2018-07-06 | 繰り返されました | Needham | Strong Buy |
| 2018-06-27 | 開始されました | Bernstein | Outperform |
| 2018-04-26 | 繰り返されました | Needham | Strong Buy |
すべてを表示
Boston Scientific Corp (BSX) 最新ニュース
iA Global Asset Management Inc. Acquires 31,717 Shares of Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific Corporation (NYSE:BSX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Oppenheimer Questions $14.5B Penumbra Deal Valuation Despite Boston Scientific’s (BSX) Mew Market Dominance - Insider Monkey
Oppenheimer Questions $14.5B Penumbra Deal Valuation Despite Boston Scientific's (BSX) Mew Market Dominance - Finviz
A Closer Look at Boston Scientific's Options Market Dynamics - Benzinga
Boston Scientific Corporation (NYSE:BSX) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance
Boston Scientific to acquire Alameda-based Penumbra for $14.5 billion - MSN
Boston Sci secures CE mark for Embold system - BioWorld MedTech
Boston Scientific Advises Removal Of Certain AXIOS Stents After Deployment Issues Surface - Benzinga
Universal Beteiligungs und Servicegesellschaft mbH Reduces Holdings in Boston Scientific Corporation $BSX - MarketBeat
Investors Purchase Large Volume of Call Options on Boston Scientific (NYSE:BSX) - MarketBeat
Boston Scientific stock rises as BSX teases new pain-therapy data while FDA stent alert hangs over shares - TechStock²
Boston Scientific has a potentially serious Axios stent recall - MassDevice
Boston Scientific stock rating reiterated at Outperform by Mizuho - Investing.com
Boston Scientific recalls stent over issue linked to 3 deaths - MedTech Dive
3 takeaways from Boston Scientific’s $14.5B Penumbra deal - MedTech Dive
Boston Scientific to Acquire Alameda-Based Penumbra for $14.5 Billion - alamedapost.com
Analysts Are Bullish on These Healthcare Stocks: Henry Schein (HSIC), Boston Scientific (BSX) - The Globe and Mail
Canaccord Genuity downgrades Penumbra stock to Hold after Boston Scientific deal - Investing.com
Penumbra shares soar pre-market — what is the Boston Scientific agreement? - MSN
Boston Scientific to Acquire Penumbra - Diagnostic and Interventional Cardiology
Boston Scientific’s Strategic Acquisition Tests Investor Resolve - AD HOC NEWS
Synthetic Absorbable Sutures Market Size to Hit USD 4.36 Billion by 2033, Driven by Rising Surgical Volumes and Minimally Invasive Procedures – SNS Insider - GlobeNewswire Inc.
Allstate Corp Has $5.31 Million Stake in Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific to acquire Penumbra, expanding cardiovascular portfolio - Today's Medical Developments
Penumbra Shares Soar Pre-MarketWhat Is The Boston Scientific Agreement? - Menafn
UnitedHealth Stock Slips Amid Medicare Investigation; Boston Scientific to Acquire Penumbra for $14.5B - Intellectia AI
Is Boston Scientific Corporation (NYSE:BSX) Worth US$88.1 Based On Its Intrinsic Value? - Yahoo Finance
Boston Scientific (BSX) Expands Urology Portfolio with Valencia Deal, Analysts Emphasize Organic Growth - Insider Monkey
Sen. Markwayne Mullin Purchases Shares of Boston Scientific Corporation (NYSE:BSX) - MarketBeat
A big acquisition decades ago almost broke Boston Scientific. Its CEO says this time is different. - Star Tribune
Boston Scientific to acquire Penumbra (NYSE: PEN) in $14.5B deal - Stock Titan
Med tech company Boston Scientific readies for new Austin offices - MSN
RTW Biotech Opp.Boston Scientific to acquire Penumbra - Research Tree
Boston Scientific (BSX) stock falls again as traders digest $14.5 billion Penumbra buy - TechStock²
Penumbra Inc. to be Sold to Boston Scientific for $374 per Share - Intellectia AI
Boston Scientific to buy Penumbra in $14.5 billion deal - AOL.com
Boston Scientific (BSX): Oppenheimer Adjusts Price Target, Maint - GuruFocus
This is Why Wall Street Firms are Bullish on Boston Scientific Corporation (BSX) - Finviz
Down 6.3% in 4 Weeks, Here's Why Boston Scientific (BSX) Looks Ripe for a Turnaround - Finviz
Truist Securities reiterates Buy rating on Boston Scientific stock - Investing.com
Boston Scientific looks to nearly double size of Minnesota facility - MassDevice
Boston Scientific (NYSE:BSX) Price Target Lowered to $100.00 at Oppenheimer - MarketBeat
Oppenheimer Adjusts Price Target on Boston Scientific to $100 From $125, Maintains Outperform Rating - marketscreener.com
Penumbra shares jump as Boston Scientific agrees to $14.5 billion takeover - MSN
Leerink Partners downgrades Penumbra stock following Boston Scientific deal - Investing.com
RTW Biotech Opportunities Portfolio Company Penumbra To Be Acquired By Boston Scientific - DirectorsTalk Interviews
Boston Scientific to acquire Penumbra for $14.5 billion - Investing.com
Truist Securities downgrades Penumbra stock to Hold following Boston Scientific acquisition - Investing.com
Boston Scientific Target of Unusually High Options Trading (NYSE:BSX) - MarketBeat
Boston Scientific Corp (BSX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):